If you have a look at the AGM Presentation, you will note that it highlights under 'Intellectual Property'...
Supporting the science behind our molecules and the rationale behind the selection of lead therapeutic targets is a robust intellectual property portfolio. With no royalty burden on lead compounds, there are seven issued patents and seven pending applications covering composition of matter, oral formulations and methods of use for NNZ-2566 across a wide range of possible uses. Remaining patent life is between 9 and 15 years not including any possible extensions of market exclusivity. For NNZ-2591, there are three issued patents and three pending applications covering composition of matter, formulations and methods of use with remaining patent life (without extensions) between 11 and 15 years.
Hope that helps.
Regards, Tony
NEU Price at posting:
7.6¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)